Drug-Coated Balloon Treatment of Femoropopliteal Lesions for Patients With Intermittent Claudication and Ischemic Rest Pain: 2-Year Results From the IN.PACT Global Study by Micari, Antonio et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2018
Drug-Coated Balloon Treatment of Femoropopliteal Lesions for Patients
With Intermittent Claudication and Ischemic Rest Pain: 2-Year Results
From the IN.PACT Global Study
Micari, Antonio; Brodmann, Marianne; Keirse, Koen; Peeters, Patrick; Tepe, Gunnar; Frost, Martin;
Wang, Hong; Zeller, Thomas; Banyai, Martin
Abstract: OBJECTIVES The IN.PACT Global Study is the largest prospective, multicenter, indepen-
dently adjudicated trial to evaluate a paclitaxel drug-coated balloon in patients with lifestyle-limiting
claudication and/or ischemic rest pain due to atherosclerotic disease of the femoropopliteal artery and
includes complex lesions beyond what are typically included in randomized controlled trials. BACK-
GROUND Randomized controlled trials have demonstrated the safety and efficacy of drug-coated bal-
loons for the treatment of Trans-Atlantic Inter-Society Consensus Document II A and B lesions, but
there is a need for large-scale prospective studies to evaluate a broader range of lesions. METHODS The
IN.PACT Global Study enrolled 1,535 subjects, and 1,406 (1,773 lesions) were included in the pre-defined
clinical cohort analysis. Freedom from clinically driven target lesion revascularization was evaluated at 24
months. The safety composite endpoint was freedom from device- and procedure-related death through 30
days and freedom from target limb major amputation and clinically driven target vessel revascularization
within 24 months. RESULTS Mean lesion length was 12.1 cm, 35.5% were total occlusions, and 18.0%
had in-stent restenosis. Freedom from clinically driven target lesion revascularization at 24 months was
83.3%, the composite safety endpoint was met in 81.7%, the 2-year all-cause mortality rate was 7.0%, and
the major target limb amputation rate was 0.7%. Increased lesion length and the presence of de novo in-
stent restenosis or coronary artery disease were associated with increased risk for clinically driven target
lesion revascularization by 24 months. CONCLUSIONS This real-world study of femoropopliteal artery
disease treatment with drug-coated balloons confirmed positive findings reported from more strictly de-
signed randomized controlled trials and showed that outcomes are durable in this population up to 2
years after treatment. (IN.PACT Global Clinical Study; NCT01609296).
DOI: https://doi.org/10.1016/j.jcin.2018.02.019
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-152341
Journal Article
Published Version
 
 
Originally published at:
Micari, Antonio; Brodmann, Marianne; Keirse, Koen; Peeters, Patrick; Tepe, Gunnar; Frost, Martin;
Wang, Hong; Zeller, Thomas; Banyai, Martin (2018). Drug-Coated Balloon Treatment of Femoropopliteal
Lesions for Patients With Intermittent Claudication and Ischemic Rest Pain: 2-Year Results From the
IN.PACT Global Study. JACC. Cardiovascular interventions, 11(10):945-953.
DOI: https://doi.org/10.1016/j.jcin.2018.02.019
2
Drug-Coated Balloon Treatment of
Femoropopliteal Lesions for Patients
With Intermittent Claudication and
Ischemic Rest Pain
2-Year Results From the IN.PACT Global Study
Antonio Micari, MD, PHD,a Marianne Brodmann, MD,b Koen Keirse, MD,c Patrick Peeters, MD,d Gunnar Tepe, MD,e
Martin Frost, PHD,f Hong Wang, MD, MPH,g Thomas Zeller, MD,h for the IN.PACT Global Study Investigators
ABSTRACT
OBJECTIVES The IN.PACT Global Study is the largest prospective, multicenter, independently adjudicated trial to
evaluate a paclitaxel drug-coated balloon in patients with lifestyle-limiting claudication and/or ischemic rest pain due to
atherosclerotic disease of the femoropopliteal artery and includes complex lesions beyond what are typically included in
randomized controlled trials.
BACKGROUND Randomized controlled trials have demonstrated the safety and efﬁcacy of drug-coated balloons for
the treatment of Trans-Atlantic Inter-Society Consensus Document II A and B lesions, but there is a need for large-scale
prospective studies to evaluate a broader range of lesions.
METHODS The IN.PACT Global Study enrolled 1,535 subjects, and 1,406 (1,773 lesions) were included in the pre-deﬁned
clinical cohort analysis. Freedom from clinically driven target lesion revascularization was evaluated at 24 months. The
safety composite endpoint was freedom from device- and procedure-related death through 30 days and freedom from
target limb major amputation and clinically driven target vessel revascularization within 24 months.
RESULTS Mean lesion length was 12.1 cm, 35.5% were total occlusions, and 18.0% had in-stent restenosis. Freedom
from clinically driven target lesion revascularization at 24 months was 83.3%, the composite safety endpoint was met in
81.7%, the 2-year all-cause mortality rate was 7.0%, and the major target limb amputation rate was 0.7%. Increased
lesion length and the presence of de novo in-stent restenosis or coronary artery disease were associated with increased
risk for clinically driven target lesion revascularization by 24 months.
CONCLUSIONS This real-world study of femoropopliteal artery disease treatment with drug-coated balloons conﬁrmed
positive ﬁndings reported from more strictly designed randomized controlled trials and showed that outcomes are durable
in this population up to 2 years after treatment. (IN.PACT Global Clinical Study; NCT01609296) (J Am Coll Cardiol Intv
2018;11:945–53) © 2018 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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F emoropopliteal artery disease is amajor cause of lifestyle-limiting clau-dication and ischemic rest pain. Drug-
coated balloons (DCBs) were developed to
overcome the limitations of standard endo-
vascular interventions, including angio-
plasty with an uncoated percutaneous
transluminal angioplasty balloon. DCBs
release the antiproliferative agent paclitaxel
onto the inner vessel wall upon inﬂation.
Both drug concentration and excipient
determine levels of persistence in the tissue,
with studies to the 180-day mark demon-
strating the long-term residence of paclitaxel
(1–3). Paclitaxel inhibits neointimal hyper-
plasia, which is a major contributor to
restenosis after angioplasty. First-in-human and
single-center studies using DCBs yielded promising
results (4–9). Randomized controlled trials (RCTs)
have demonstrated the safety and efﬁcacy of DCBs
for the treatment of Trans-Atlantic Inter-Society
Consensus Document (TASC) II A and B lesions
(10–16). However, data continue to be limited on
DCBs for more complex lesions that can affect real-
world patients seen in everyday practice (17–21).
These include longer TASC II C and D lesions, reste-
notic lesions, calciﬁed lesions, and other lesion types
that are often excluded from RCTs with selective
enrollment criteria. Although these studies were
similar for evaluating lesions that are typically
excluded from RCTs, the types and levels of evidence
vary between each study.
There is a need for large-scale studies to examine
DCBs in patients with a broad range of femo-
ropopliteal lesions, and the IN.PACT Global Study is
the largest prospective, multicenter trial to evaluate
the safety and efﬁcacy of a paclitaxel DCB (IN.PACT
Admiral, Medtronic, Dublin, Ireland) for the treat-
ment of patients with lifestyle-limiting claudication
and/or ischemic rest pain due to atherosclerotic dis-
ease of the femoropopliteal artery, including the
entire native superﬁcial femoral artery (SFA) and/or
popliteal artery (P1 to P3) starting from the SFA
origin. Previously reported results demonstrated
consistent efﬁcacy and safety through 1 year (22).
Safety and efﬁcacy outcomes are reported through
2 years.
METHODS
IN.PACT GLOBAL STUDY: DESIGN, SUBJECTS, AND
TREATMENT. The IN.PACT Global Study is a pro-
spective, multicenter, international, single-arm clin-
ical study assessing the safety and effectiveness of a
paclitaxel-coated DCB for the treatment of real-
world patients with atherosclerotic disease of the
femoropopliteal artery. The trial is registered as
NCT01609296. Subjects with symptoms of intermit-
tent claudication and/or ischemic rest pain (Ruth-
erford class 2 to 4) and angiographic evidence of
severe stenosis or occlusion (length $2 cm; de novo or
restenosis, in-stent or not in-stent) in the entire
femoropopliteal artery, including the entire native
SFA and/or popliteal artery (P1 to P3), were eligible for
enrollment. Details of study design and treatment
have been described (22).
The Institutional Review Board or ethics commit-
tee at each study site approved the study protocol.
Informed consent was obtained from all subjects
before enrollment. The study was conducted in
accordance with the Declaration of Helsinki, good
clinical practice guidelines, and applicable laws as
speciﬁed by all relevant governmental bodies.
CLINICAL COHORT STUDY ENDPOINTS. An inde-
pendent clinical events committee (CEC) (Syntactx,
New York, New York) was established to assess the
primary and select secondary endpoints and to
determine whether each met protocol-speciﬁed
criteria. The CEC was composed of interventional
and noninterventional clinicians with pertinent
expertise who were not participants in the study and
did not have any conﬂicts of interest.
The primary safety composite endpoint was
freedom from device- and procedure-relatedmortality
through 30 days and freedom from major target limb
amputation and clinically driven (CD) target vessel
revascularization (TVR) within 12 months after the in-
dex procedure. CD TVR was assessed at the subject
level and deﬁned as the ﬁrst event that required CD
TVR in the subject. The primary effectiveness endpoint
SEE PAGE 954
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was freedom from CD target lesion revascularization
(TLR) within 12 months. The safety and efﬁcacy end-
points were assessed at 24 months and thereafter as
co–secondary endpoints. The CEC reviewed all TLR
and TVR events to determine which were CD, deﬁned
as any reintervention within the target lesion(s)
because of symptoms or ankle-brachial index decrease
of$20% or>0.15 comparedwith post–index procedure
baseline ankle-brachial index. CD TLR and TVR did not
include those procedures that were performed on
asymptomatic subjects or were based only on diag-
nostic imaging procedures. Secondary endpoints
included primary sustained clinical improvement
(deﬁned as freedom from major target limb amputa-
tion, freedom from TVR, and increase of at least 1 class
in the Rutherford clinical category), CD TLR, CD TVR,
any TLR, any TVR, and the incidence of major adverse
events (all-cause mortality, CD TVR, major target limb
amputation, and thrombosis at the target lesion site) at
24 months. The CEC adjudicated all major adverse
events. Functional assessments included evaluation
of walking capacity with the Walking Impairment
Questionnaire and quality of life with the EuroQol-5D
index.
Pre- and post-dilatation were permitted at the
discretion of the investigator. Provisional stenting
was allowed if 1 of the criteria was not met despite
repeated and prolonged balloon inﬂations: ﬂow-
limiting dissection, visually estimated residual ste-
nosis $50%, or translesional gradient >10 mm Hg.
For categories of provisional stenting, spot stenting
was deﬁned as use of the single shortest stent in
which minimal length was sufﬁcient to cover the
residual stenosis but did not cover the entire original
length of the target lesion, and partial lesion
coverage was use of a stent length longer than the
residual stenosis but shorter than the original length
of the target lesion.
CLINICAL COHORT STATISTICAL ANALYSIS. All an-
alyses were based on the intent-to-treat principle.
All summaries were based on nonmissing assess-
ments. Unless otherwise speciﬁed, all baseline
demographics and clinical characteristics were
summarized on a subject basis; lesion characteris-
tics were summarized on a lesion basis. For base-
line characteristics, continuous variables are
described as mean  SD; dichotomous and cate-
gorical variables are described as counts and pro-
portions. The Kaplan-Meier method was used to
evaluate time-to-event data for freedom from CD
TLR over the 24-month follow-up period. The
outcome analysis was performed at a subject level.
For event rates that were expressed as a
proportion, the number of subjects with events
within 720 days was the numerator, and the total
number of subjects with events or at least 660 days
of clinical follow-up was the denominator. For
assessment of clinical characteristics at 24 months,
subjects were required to have data at baseline and
24 months. A Cox proportional hazards model with
potential baseline predictors was ﬁtted on CD TLR
through 720 days, and a stepwise selection process
with an entry criterion of 0.20 and a stay criterion
of 0.10 was used (see the Online Appendix for
baseline predictors tested). Statistical analyses were
performed using SAS version 9.4 (SAS Institute,
Cary, North Carolina).
RESULTS
BASELINE SUBJECT AND LESION CHARACTERISTICS. The
IN.PACT Global Study enrolled a total of 1,535 sub-
jects. The full clinical cohort within the IN.PACT
FIGURE 1 Patient Flow Diagram Through 24 Months
Patient follow-up is displayed through 24 months. A total of
1,406 intent-to-treat patients were included in this analysis.
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Global Study included 1,416 subjects, of whom 1,406
were treated with the paclitaxel DCB and included in
the intent-to-treat group. Clinical follow-up is shown
in Figure 1. The rate of compliance for follow-up
within the pre-speciﬁed window was 77.6% (n ¼ 930
of 1,199). Baseline demographics and characteristics
are reported in Tables 1 and 2.
Provisional stents were implanted in 353 patients
(25.3%) and 373 lesions (21.2%) (Table 2). Of these,
24.4% (n ¼ 91 of 373) were spot stented, 37.8%
(n ¼ 141 of 373) were partial lesion coverage, and
37.8% (n ¼ 141 of 373) were whole lesion coverage.
EFFECTIVENESS OUTCOMES. The Kaplan-Meier es-
timate of freedom from CD TLR was 83.3% at 24
months (Figure 2). The rate of CD TLR at 24 months
was 16.9% (n ¼ 214 of 1,269). Of these, 13 events
occurred in the ﬁrst 30 days after the index proced-
ure, and the Kaplan-Meier estimate of freedom from
CD TLR was 99.1%. The mean time to ﬁrst CD TLR
was 342.7  197.3 days. Primary sustained clinical
improvement was achieved by 68.6% of subjects
(n ¼ 737 of 1,075).
A post hoc analysis was performed to compare
effectiveness outcomes in subgroups deﬁned by the
presence of baseline clinical or procedural character-
istics (Figure 3, Table 3).
Lesions $15 cm and lesions with popliteal
involvement had signiﬁcantly higher rates of CD TLR
through 24 months (p < 0.001). The mean lesion
length was 13.4  9.1 cm for subjects with SFA-alone
lesions and 17.4  10.6 cm for subjects with lesions
that had popliteal artery involvement (p < 0.001).
TABLE 1 Baseline Demographics and Clinical Characteristics of
Subjects in the Clinical Cohort (n ¼ 1,406)*
Age, yrs 68.6  10.1 (1,396)
Male 67.8 (953/1,406)
Body mass index, kg/m2 26.7  4.5 (1,391)
Obesity (body mass index $30 kg/m2) 20.5 (285/1,391)
Diabetes mellitus 39.9 (560/1,402)
Insulin dependent diabetes mellitus 17.8 (249/1,402)
Hypertension 83.4 (1169/1,401)
Hyperlipidemia 70.5 (960/1,362)
Current smoker 31.8 (447/1,406)
Coronary heart disease 40.5 (540/1,332)
Carotid artery disease 20.2 (241/1,196)
Renal insufﬁciency† 11.2 (136/1,217)
Previous peripheral revascularization 52.4 (737/1,406)
Below-the-knee disease of target leg 45.3 (594/1,310)
Rutherford class
0 0.0 (0/1,403)
1 0.1 (1/1,403)‡
2 31.1 (436/1,403)
3 57.7 (810/1,403)
4 8.6 (120/1,403)
5 2.6 (36/1,403)‡
6 0.0 (0/1,403)
ABI§, mm Hg, per target limb 0.678  0.218 (1,395)
Bilateral disease 8.4 (118/1,406)
Values are mean  SD (N) or % (n/N). *Summaries are based on nonmissing as-
sessments. In some cases, baseline demographic or clinical data were not avail-
able, and therefore the total number of subjects for that variable is <1,406.
†Deﬁned as baseline creatinine $1.5 mg/dl. ‡Because of protocol violations, one
Rutherford class 1 subject and 36 Rutherford class 5 subjects were enrolled and
included in the analysis. §For subjects with bilateral disease, ABI is included for
each target limb.
ABI ¼ ankle-brachial index.
TABLE 2 Lesion Characteristics From Subjects in the
Clinical Cohort (n ¼ 1,406, 1,773 Lesions)*
Pre-procedure
Lesion type
De novo 74.3 (1,317/1,773)
Restenotic (nonstented) 7.7 (136/1,773)
In-stent restenosis 18.0 (320/1,773)
Vessel
Superﬁcial femoral artery 87.6 (1,553/1,773)
Proximal popliteal artery 27.3 (484/1,773)
Lesion length, cm 12.09  9.54 (1,773)
Occluded 35.5 (629/1,773)
With calciﬁcation 68.7 (1,217/1,771)
With severe calciﬁcation† 10.2 (181/1,771)
Reference vessel diameter, mm 5.186  0.681 (1,773)
Diameter stenosis, % 88.8  12.3 (1,773)
Procedure
DCBs per lesion 1.7  1.0 (1,766)
Pre-dilatation 78.0 (1,097/1,406)
Post-dilatation 35.1 (491/1,397)
Provisional stenting 21.2 (373/1,761)
Provisional stents per lesion 1.3  0.6 (373)
Post-procedure
Device success‡ 99.4 (2,984/3,002)
Procedural success§ 99.3 (1,386/1,396)
Clinical success¶ 98.8 (1,379/1,396)
Dissections
0 56.8 (1,006/1,772)
A–C 35.4 (627/1,772)
D–F 7.8 (139/1,772)
Values are % (n/N) or mean  SD (N). *Summaries are based on nonmissing as-
sessments. In some cases, baseline or clinical data were not available, and
therefore the total number of lesions for that variable is <1,773. †Severe calciﬁ-
cation deﬁned as calciﬁcation with circumference $180 (both sides of vessel at
the same location) and length greater than or equal to one-half of the total lesion
length. ‡Device success deﬁned as successful delivery, inﬂation, deﬂation, and
retrieval of the intact study balloon device without burst below the rated burst
pressure. This analysis is device (balloon) based. §Procedural success deﬁned as
residual stenosis of #50% for nonstented subjects or #30% for stented subjects
by core laboratory assessment (site-reported estimate was used if core laboratory
assessment was not available). This analysis is lesion based. ¶Clinical success
deﬁned as procedural success without procedural complications (death, major
target limb amputation, thrombosis of the target lesion, or target vessel revas-
cularization) before discharge. This analysis is subject based.
DCB ¼ drug-coated balloon.
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SAFETY OUTCOMES. Safety outcomes are reported in
Table 4. Major target limb amputation was required in
0.7% of subjects (n ¼ 9 of 1,269). The average time to
amputation was 310.2  174.1 days. Three subjects
had major target limb amputations at 12 months, and
an additional 6 subjects had amputation by 24
months. The 3 subjects with amputation at 12 months
were in Rutherford classes 3, 4, and 5 at baseline (the
Rutherford class 5 patient was enrolled as a protocol
deviation). The average age of the 6 subjects who
required major target limb amputation between the
ﬁrst and second years after the index procedure was
68  10.5 years, 4 were male, 3 had diabetes mellitus,
and 4 had previous peripheral vascular disease. Two
of the subjects were in Rutherford class 2, 3 were in
class 3, and 1 was in class 4. Mean lesion length was
17.4  8.9 cm.
The rate of all-cause death was 7.0% (n ¼ 89 of
1,269) at 24 months (which does not include deaths
that occurred during the 2-month extension
follow-up). Independent adjudication by the CEC
determined that none of the deaths were related to
the study device, and 3 of the deaths were possibly or
potentially related to the study procedure, as any
death within 30 days of the index was adjudicated by
the CEC as procedure related. Details of the possibly
procedure-related events have been previously re-
ported (22).
FUNCTIONAL OUTCOMES. Mean score on the
EuroQol-5D index was 0.6089  0.2994 at baseline
(n ¼ 1,382) and 0.7744  0.2551 (n ¼ 964) at 24
months. The mean change from baseline in EuroQol-
5D index score at 24 months was 0.1495  0.3346
(n ¼ 951). The mean ankle-brachial index at 24
months was 0.896  0.226, and the change from
baseline was 0.220  0.263 (p < 0.001). Changes in
Rutherford values are shown in Table 5.
Mean overall walking impairment score by the
Walking Impairment Questionnaire was 33.8  26.9 at
baseline (n ¼ 1,356) and 75.1  30.9 (n ¼ 952) at 24
months.
MULTIVARIATE ANALYSIS. A multivariate Cox pro-
portional hazards regression analysis was performed
to identify potential baseline predictors of CD TLR in
the clinical cohort through 24 months. Increasing
lesion length, presence of de novo in-stent restenosis,
and presence of coronary artery disease were associ-
ated with increased risk for CD TLR by 24 months.
Unilateral disease, SFA-alone lesions, increasing
reference vessel diameter, increasing age, and
absence of target limb posterior tibial artery pulse
were associated with reduced risk for CD TLR
(Table 6).
DISCUSSION
One-year outcomes from the IN.PACT Global Study
showed that treatment with a paclitaxel DCB was
safe and effective in the full clinical cohort, consis-
tent with the results of RCTs of patients with TASC II
A and B lesions that are less challenging to treat
(15,22). Two-year outcomes show that the safety and
effectiveness of a paclitaxel DCB is durable in this
same patient cohort. The DCB had a good safety
proﬁle, and Kaplan-Meier estimate of freedom from
CD TLR at 24 months was 83.3%. This is consistent
with 2-year outcomes reported from the randomized
IN.PACT SFA trial of the same paclitaxel DCB
(IN.PACT Admiral), with the Kaplan-Meier estimate
of freedom from CD TLR being 91.0% at 24 months
and a mean time to ﬁrst CD TLR of 351.9  165.9 days
(11). Notably, the IN.PACT SFA trial evaluated sub-
jects and/or lesions that were less challenging to
treat than in the IN.PACT Global Study. In the
IN.PACT SFA trial, mean lesion length was 8.94 cm,
25.8% of lesions were total occlusions, and 8.1%
were severely calciﬁed (11). In the IN.PACT Global
Study, mean lesion length was 12.1 cm, 35.5% of
FIGURE 2 Kaplan-Meier Curve of Freedom From Clinically Driven Target Lesion
Revascularization in the Clinical Cohort Through 24 Months
Number at risk represents the number at the beginning of the 60-day window before
each follow-up interval.
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lesions were total occlusions, and 10.2% were
severely calciﬁed. Importantly, calcium deﬁnitions
between these trials were different.
The 2-year results of the IN.PACT Global full clin-
ical cohort are similar to what has been reported from
the Lutonix Global SFA registry study of the Lutonix
035 DCB (Bard Lutonix, New Hope, Minnesota) in a
heterogeneous population of real-world patients (20).
The Kaplan-Meier estimate of TLR-free survival at 24
months was similar but slightly higher in the overall
population and several of the same subgroups
compared with those that were analyzed in the
IN.PACT Global clinical cohort (overall cohort, 90.3%
Lutonix vs. 83.3% IN.PACT Admiral; occluded lesions,
90.6% Lutonix vs. 81.4% IN.PACT Admiral; long le-
sions, 89.4% Lutonix [$14 cm] vs. 78.8% IN.PACT
Admiral [$15 cm]), though the performance of indi-
vidual DCBs cannot be compared in the absence of a
direct head-to-head comparison (20). The subject
populations were generally similar between the 2
studies, though a higher percentage of subjects in the
IN.PACT Global Study had calciﬁed lesions at baseline
(68.7% IN.PACT Global vs. 50.2% Lutonix Global) (20).
Another important difference between the studies
was the use of a CEC in the IN.PACT Global Study to
adjudicate all major adverse events and determine
which TLR events were CD.
In the IN.PACT Global clinical cohort, the long
mean time to ﬁrst CD TLR (342.7  197.3 days) and the
absence of a spike in CD TLR events in the immediate
post-procedural period (only 13 events in the ﬁrst 30
days) suggest that most reinterventions were due to
FIGURE 3 Kaplan-Meier Curves of Freedom From Clinically Driven Target Lesion Revascularization in the Clinical Cohort Through 24 Months by
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physiological failure (e.g., neointimal hyperplasia)
and/or disease progression as opposed to mechanical
failure (e.g., acute recoil).
A post hoc analysis showed that in most cases, DCB
performance was similar between subgroups that
were deﬁned by the presence of a key clinical or
procedural characteristic. Freedom from CD TLR by
Kaplan-Meier estimate at 24 months was not statis-
tically signiﬁcantly different between subjects with
or without pre-dilatation, post-dilatation, severe
calciﬁcation, total occlusions, or provisional stenting.
In each of these subgroup comparisons, the similarity
in clinical outcomes supports the conclusion that
DCBs are consistently effective across a broad range
of lesion types.
A multivariate regression analysis identiﬁed
baseline clinical and lesion characteristics that were
signiﬁcantly associated with outcomes in the clin-
ical cohort. Increasing lesion length was positively
associated with increased risk for reintervention
within 24 months, which is consistent with other
reports that have identiﬁed lesion length as a pre-
dictor of TLR or restenosis after endovascular in-
terventions, such as standard angioplasty with
stenting (23–25). Lesion location was also identiﬁed
as a predictor of reintervention in the clinical
TABLE 3 Clinically Driven Target Lesion Revascularization
Outcomes by Subgroup
Subgroup
Kaplan-Meier
Estimate of Freedom
From CD TLR at 720 Days
Log-Rank
p Value
Stented subjects 80.8% (n ¼ 353) 0.206
Nonstented subjects 83.9% (n ¼ 1,044)
Subjects with pre-dilatation 82.8% (n ¼ 1,097) 0.414
Subjects without pre-dilatation 84.9% (n ¼ 309)
Subjects with post-dilatation 83.7% (n ¼ 491) 0.754
Subjects without post-dilatation 82.9% (n ¼ 906)
Lesions $15 cm 78.8% (n ¼ 559) <0.001
Lesions <15 cm 86.2% (n ¼ 847)
Occluded target lesion 81.4% (n ¼ 604) 0.051
Stenosed target lesion 84.7% (n ¼ 802)
Severely calciﬁed lesion 80.2% (n ¼ 337) 0.234
Not severely calciﬁed lesion 83.4% (n ¼ 668)
SFA alone 86.0% (n ¼ 952) <0.001
Popliteal involvement 75.1% (n ¼ 353)
CD ¼ clinically driven; SFA ¼ superﬁcial femoral artery; TLR ¼ target lesion
revascularization.
TABLE 4 24-Month Safety Outcomes* in the Clinical Cohort
(n ¼ 1,269)†
CD TLR‡ 214 (16.9)
Time to ﬁrst CD TLR, days 342.7  197.3 (214)
Primary safety endpoint§ 1,037 (81.7)
Major adverse events¶ 314 (24.7)
Death (all-cause) 89 (7.0)
Major target limb amputation, n (%) 9 (0.7)
Thrombosis 57 (4.5)
CD TVR 224 (17.7)
Any TLR 218 (17.2)
Any TVR 229 (18.0)
Values are n (%) or mean  SD (n). *An independent clinical events committee
adjudicated all major adverse events. †Event rates expressed as a proportion: the
number of subjects with events is the numerator, and the number of subjects with
at least 660 days of clinical follow-up is the denominator. ‡CD TLR deﬁned as any
reintervention within the target lesion(s) due to symptoms or drop of ABI
of $20% or >0.15 compared with post–index procedure baseline ABI. §The pri-
mary safety composite endpoint was freedom from device- and procedure-related
mortality through 30 days, and freedom from major target limb amputation and
CD TVR within 12 months post–index procedure. ¶Major adverse event deﬁned as
all-cause mortality, CD TVR, major target limb amputation, thrombosis at the
target lesion site.
TVR ¼ target vessel revascularization; other abbreviations as in Tables 1 and 3.
TABLE 5 Rutherford Outcomes Through 24 Months
Change in Rutherford Class Through 24 Months
5 0.6% (6/1,013)
4 5.3% (54/1,013)
3 33.6% (340/1,013)
2 33.0% (334/1,013)
1 15.1% (153/1,013)
0 10.0% (101/1,013)
þ1 1.5% (15/1,013)
þ2 0.9% (9/1,013)
þ3 0.1% (1/1,013)
þ4 0.0% (0/1,013)
p value <0.001
Values are % (n/N).
TABLE 6 Baseline Predictors of Clinically Driven Target Lesion
Revascularization in the Clinical Cohort Through 24 Months
Coefﬁcient SE
Hazard Ratio
(95% CI)
p
Value
Total lesion length 0.037 0.007 1.037 (1.022–1.053) <0.001
Target limb (unilateral vs.
bilateral)
0.747 0.226 0.474 (0.305–0.737) <0.001
Target lesion location (SFA alone
vs. SFA þ popliteal)
0.514 0.165 0.598 (0.433–0.827) 0.002
Age 0.020 0.008 0.980 (0.965–0.994) 0.007
Reference vessel diameter 0.314 0.121 0.730 (0.576–0.925) 0.009
Target lesion type (de novo ISR
vs. not de novo ISR)
0.467 0.180 1.596 (1.122–2.269) 0.009
Target limb posterior tibial
artery pulse (absent vs.
present)
0.489 0.209 0.613 (0.407–0.924) 0.019
Coronary artery disease
(present vs. absent)
0.329 0.161 1.389 (1.013–1.905) 0.041
Multivariate predictors were chosen by a stepwise procedure using an entry criterion of 0.20 and
a stay criterion of 0.10. Baseline characteristics were evaluated for potential predictive associa-
tions by multiple Cox proportional hazards regression analysis.
CI ¼ conﬁdence interval; ISR ¼ in-stent restenosis; SFA ¼ superﬁcial femoral artery.
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cohort, with SFA-alone lesions (no popliteal
involvement) being associated with reduced risk for
CD TLR within 24 months. This is consistent with
the ﬁnding that Kaplan-Meier estimate of freedom
from CD TLR within 24 months was signiﬁcantly
higher in the SFA-alone group compared with
the popliteal-involvement group and, to our
knowledge, is the ﬁrst report of lesion location
being identiﬁed as a predictor of CD TLR in
femoropopliteal disease.
The rate of all-cause mortality was 7.0% at 24
months, up from 3.5% at 12 months (22). None of the
deaths between 12 and 24 months were procedure or
device related, on the basis of independent adjudi-
cation by the CEC. A similar all-cause death rate was
reported in the Lutonix Global trial: 2.8% at 12
months and 5.9% at 24 months.
STUDY LIMITATIONS. The study was a single-arm
trial. In the absence of a control or active compar-
ator, the results cannot support direct comparison
with other endovascular treatment modalities. Also,
the evaluation of DCB effectiveness was limited to
clinical outcomes in this full clinical cohort. Not all
patients had data available for the analysis of
anatomic outcomes, as only pre-deﬁned cohorts (long
lesion, de novo in-stent restenosis, and chronic total
occlusion) were planned for prospective duplex ul-
trasound and imaging analyses.
CONCLUSIONS
Results of the IN.PACT Global Study clinical cohort
analysis showed durable safety and efﬁcacy of the
paclitaxel IN.PACT Admiral DCB through 2 years in
patients with a range of lesion types in the SFA and/or
popliteal arteries, which is consistent with reports of
positive outcomes from RCTs of paclitaxel DCBs in
TASC II A and B lesions.
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